Radiopharm Theranostics Advances Brain Metastasis Imaging with 18F-RAD101

Radiopharm Theranostics Limited (ASX: RAD), a clinical-stage biopharmaceutical company, has commenced its U.S. Phase 2b study, dosing the first patient with its novel imaging agent 18F-RAD101. The trial focuses on assessing the diagnostic accuracy of 18F-RAD101 for recurrent brain metastases arising from solid tumors. Targeting fatty acid synthase (FASN), which is overexpressed in many tumors, the agent aims to differentiate true tumor progression from treatment effects, improving diagnostic precision. Encouraging Phase 2a results from Imperial College London have demonstrated significant tumor uptake across various cancers. Partnering with BAMF Health, known for its integrated clinical trial platform, Radiopharm aims to revolutionize brain metastasis imaging. With over 300,000 brain metastasis cases annually in the U.S., the innovation holds significant clinical promise. Radiopharm’s broader pipeline includes multiple oncology trials across lung, breast, and brain cancers, reflecting its commitment to developing next-generation radiopharmaceuticals for high unmet medical needs.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com